Patients with myelodysplastic syndrome (MDS) and secondary myeloid leukemia (sAML) with TP53 mutations have a poor prognosis, with a median overall survival of 6–12 months regardless of the treatment. The gene discussed is TP53; the disease is myelodysplastic syndrome.